For decades, mitochondria were understood primarily as the cell’s energy generators. That understanding has since expanded significantly. Research has established that mitochondria also function as active signaling hubs — producing molecules that communicate with the rest of the cell and even with distant tissues. MOTS-c is one of the most studied of these mitochondrial-derived signals, and the research literature on it has grown substantially since its initial characterization in 2015.
Nicotinamide adenine dinucleotide — more commonly referenced as NAD+ — is a coenzyme found in every living cell and has become one of the most actively researched molecules in longevity and metabolic biology over the past two decades. A 2026 PRISMA-guided systematic review in ScienceDirect noted that NAD+ research has expanded dramatically, with studies spanning preclinical models through human interventional trials examining its role across a wide range of biological processes. This post provides a research-focused overview of what the peer-reviewed literature has explored regarding NAD+ and its decline with age.
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide derived from prothymosin alpha, a protein produced by the thymus gland. First isolated by Allan Goldstein and colleagues in the 1970s, it has since accumulated one of the most extensive peer-reviewed research profiles of any immunomodulatory peptide in the scientific literature. This post covers what that research has actually explored — the mechanisms, the study findings, and the areas where Tα1 continues to generate scientific interest.
